{"description":"no data was collected. Adverse Events Description text only refers to the Cohort II No participants were enrolled in Cohort I, so no adverse events were monitored/assessed for Cohort I","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":0,"description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Cohort I (Initial IHC Within 42 Days)"},{"deathsNumAffected":0,"deathsNumAtRisk":2,"description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"EG001","otherNumAffected":2,"otherNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"Cohort II (Initial IHC Within 70 Days or After Relapse)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":2,"numAtRisk":2}],"term":"General disorders and administration site conditions"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":2,"numAtRisk":2,"numEvents":5}],"term":"Investigations"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Eye disorders"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Metabolism and nutrition disorders"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Nervous system disorders"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Musculoskeletal and connective tissue disorders"}],"timeFrame":"Up to 8 weeks after last protocol treatment"}